Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
Journal of Experimental Medicine, 2020•rupress.org
Disclosures: Dr. Badhai reported a patent to 19209921.8-1112 pending. Dr. Monkhorst
reported personal fees from Roche, personal fees from Pfizer, personal fees from BMS,
personal fees from Abbvie, personal fees from AstraZeneca, non-financial support from
Roche, non-financial support from Takeda, non-financial support from Pfizer, personal fees
from MSD, grants from AstraZeneca, and grants from Roche outside the submitted work. Dr.
van Lohuizen reported a patent to 18209921.8 pending. Dr. Berns reported a patent to …
reported personal fees from Roche, personal fees from Pfizer, personal fees from BMS,
personal fees from Abbvie, personal fees from AstraZeneca, non-financial support from
Roche, non-financial support from Takeda, non-financial support from Pfizer, personal fees
from MSD, grants from AstraZeneca, and grants from Roche outside the submitted work. Dr.
van Lohuizen reported a patent to 18209921.8 pending. Dr. Berns reported a patent to …
Disclosures: Dr. Badhai reported a patent to 19209921.8-1112 pending. Dr. Monkhorst reported personal fees from Roche, personal fees from Pfizer, personal fees from BMS, personal fees from Abbvie, personal fees from AstraZeneca, non-financial support from Roche, non-financial support from Takeda, non-financial support from Pfizer, personal fees from MSD, grants from AstraZeneca, and grants from Roche outside the submitted work. Dr. van Lohuizen reported a patent to 18209921.8 pending. Dr. Berns reported a patent to 19209921.8-1112 pending. No other disclosures were reported.
rupress.org
以上显示的是最相近的搜索结果。 查看全部搜索结果